Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Integrating DNA Methylation and Drug Abundance at Single-Cell Resolution to Predict Cancer Drug Sensitivity

Objectif

One of the greatest challenges in cancer therapy is treatment resistance, which arises from the selection of pre-existing cell states carrying survival advantages during treatment. Although genetic alterations have been extensively studied, genetics alone accounts for only a subset of relapses observed in clinical settings. EPI-SENSOR proposes that therapy response is driven by epigenetic divergence – the extent to which a tumor cell’s epigenetic state deviates from its cell-of-origin. I hypothesize that pre-existing epigenetic divergence determines whether individual cancer cells are sensitive or resistant to therapy. Testing this hypothesis requires a joint characterization of genetic mutations, differentiation state, epigenetic patterns, and drug abundance within a single cell - a level of integration that has not previously been possible. This underscores the need for novel research methods. We have developed innovative single-cell epigenomic technologies and computational tools that enable us to test our hypothesis. Using acute myeloid leukemia as a cancer model system, EPI-SENSOR will profile longitudinal patient samples at diagnosis and during cancer treatment, utilizing joint profiling of DNA methylation, somatic mutations, and surface protein expression in single cells. This approach will enable us to understand which molecular mechanisms determine sensitive or resistant cell phenotypes. Furthermore, we will develop a novel approach that tags cancer drugs with an oligonucleotide compatible with single-cell readouts. This approach will quantify cancer drug abundance and DNA methylation states at the single-cell level. Finally, we will develop a prognostic tool based on bulk DNA methylation data to implement EPI-SENSOR in clinical practice. All of these approaches combined will reveal non-genetic mechanisms of therapy resistance, define predictive DNA methylation signatures, and provide translational tools for personalized cancer treatment.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC - HORIZON ERC Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-STG

Voir tous les projets financés au titre de cet appel

Institution d’accueil

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Contribution nette de l'UE
€ 1 499 423,00
Adresse
IM NEUENHEIMER FELD 280
69120 Heidelberg
Allemagne
Région
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Type d’activité
Research Organisations
Liens
Coût total
€ 1 499 423,00

Bénéficiaires (1)